argenx SE operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares argenx SE with three other
miscellaneous service companies in Europe:
sales of 25.50 million Euros [US$30.36 million]
(32.70 million Euros [US$38.93 million]
of which 100%
was Pharmaceutical), and
Brain Biotechnology Research and Information Network AG
based in GERMANY
(39.06 million Euros [US$46.50 million]
of which 64%
argenx SE reported sales of 36.43 million Euro (US$43.36 million)
December of 2020.
decrease of 47.8%
versus 2019, when the company's sales were 69.78 million Euro.
Contributing to the drop in overall sales was the 89.2% decline
in Milestone Payments, from 28.09 million Euro to 3.02 million Euro.
There were also decreases in sales in
Research and Development Service Fees (F (down 84.2% to 3.06 million Euro)
However, these declines were partially offset by the increase in sales of
Upfront Payments (up 35.7% to 30.35 million Euro)